Connect with us

Health

US Approves New Drug To Delay Type 1 Diabetes 

Published

on

A new drug that delays the onset of type 1 diabetes received approval from the US Food and Drug Administration.
It is the first therapy approved for prevention of type 1 diabetes.
The monoclonal antibody teplizumab, which will be marketed under the brand name Tzield, from ProventionBio and Sanofi is given through intravenous infusion. The therapy will carry a wholesale cost of roughly $194,000 for a full course of treatment, the drug’s manufacturer said in an investor call on Friday, although this is not expected to be the price consumers would pay.
It is thought to work by turning down the body’s misdirected attack on its own insulin-producing cells. The idea is that protecting these cells buys people more time before they become dependent on insulin to manage their condition.
In clinical trials, Tzield delayed progression to full-blown diabetes by a little over two years. But the benefits have lasted much longer in some of the study participants.
One of them, Mikayla Olsten, was screened for diabetes after her 9-year old sister, Mia, suddenly developed a life-threatening episode of diabetic ketoacidosis and was diagnosed with diabetes. There was no history of diabetes in the family, and Mikayla was not sick, but she had four of the five types of autoantibodies that doctors look for to assess a person’s risk.
“They told us when somebody has that many markers, it’s not if they’re going to develop diabetes, it’s when,” said her mom, Tracy.
Mikayla was 15 when she joined the study and received teplizumab. She is now 21 and a senior in college. She gets an annual battery of tests to check her pancreas and blood markers, and Tracy Olsten says her condition has not progressed in six years.
According to a scientific statement from JDRF, the Endocrine Society and the American Diabetes Association, when a person has markers for autoimmune disease and episodes of uncontrolled blood sugar, the five-year risk for progression to insulin-dependent symptomatic disease is 75 percent. The lifetime risk of developing insulin-dependent diabetes is nearly 100 percent.

Continue Reading

Health

RSG Plans Fresh Training For TBAs

Published

on

Plans are in the works by the authorities in the Rivers State Ministry of Health to conduct training for Traditional Birth Attendants(TBAs) in the State.
State Commissioner for Health, Dr. Adaeze Oreh gave the hint while chatting with newsmen recently in Port Harcourt.
She said the training has become crucial to school the TBAs on methods and measures to complement in maternal health care.
In her words,”  We are aware of of their roles, but we need to be confident that they can still play that role, especially the skills set needed to complement what government is doing.’’
Dr. Oreh explained that maternal and child care has evolved, hence, the TBAs need to be schooled,” we want them to scale up their skills, especially on high risk pregnancies.”
She continued, “ We want to make sure that our system mops up those high risk pregnancies, because we know that many of them carry out clandestine activities they are not helping us.”
Assuring of improved manpower in the State health sector, Dr. Oreh said the Governor Siminalayi Fubara administration has embarked on fresh recruitment exercise for health workers to meet current challenges.
She assured that once the recruitment exercise is completed, the various health centres and hospitals will be staffed with qualified manpower to provide efficient health services in the State.

Kevin Nengia

Continue Reading

Health

Viral Hepatitis Claims 3,500 Lives Daily -WHO

Published

on

The World Health Organisation (WHO) has raised an alarm on viral hepatitis infection that claims 3,500 lives each day.
According to the World Health Organisation (WHO) 2024 Global Hepatitis Report, the number of lives lost due to the viral hepatitis is increasing.
The disease is the second leading infectious cause of death globally — with 1.3 million deaths per year, the same as tuberculosis, a top infectious killer.
The report, released at the World Hepatitis Summit revealed that despite better tools for diagnosis and treatment, and decreasing product prices, testing and treatment coverage rates have stalled.
It, however, said, reaching the WHO elimination goal by 2030 is still  achievable, if swift actions are taken now.
New data from 187 countries show that the estimated number of deaths from viral hepatitis increased from 1.1 million in 2019 to 1.3 million in 2022. Of these, 83percent were caused by hepatitis B, and 17percent by hepatitis C. Every day, there are 3,500 people dying globally due to hepatitis B and C infections.
“This report paints a troubling picture: despite progress globally in preventing hepatitis infections, deaths are rising because far too few people with hepatitis are being diagnosed and treated,” said WHO’s Director-General, Dr Tedros Adhanom Ghebreyesus.
He added, “WHO is committed to supporting countries to use all the tools at their disposal – at access prices – to save lives and turn this trend around.”
Updated WHO estimates indicate that 254 million people lived with hepatitis B and 50 million with hepatitis C in 2022. Half the burden of chronic hepatitis B and C infections is among people 30–54 years old, with 12percent among children under 18 years of age. Men account for 58percent of all cases.
New incidence estimates indicate a slight decrease compared to 2019, but the overall incidence of viral hepatitis remains high.
In 2022, there were 2.2 million new infections, down from 2.5 million in 2019.
These include 1.2 million new hepatitis B infections and nearly one million new hepatitis C infections. More than 6,000 people are getting newly infected with viral hepatitis each day.
The revised estimates are derived from enhanced data from national prevalence surveys. They also indicate that prevention measures such as immunisation and safe injections, along with the expansion of hepatitis C treatment, have contributed to reducing the incidence.

Continue Reading

Health

How Dates Boost Fertility -Research

Published

on

Now, researchers in a study, suggest that date palm is an arsenal to fight infertility in couples. They found that 1-month consumption of date palm has a positive impact on the sexual function of infertile couples.
The study to investigate the effect of date palms on the sexual function of infertile couples  was in the 2022 edition of the BMC Research Notes.
In a double-blind, placebo-controlled clinical trial conducted on infertile women and their husbands who were referred to infertility clinics in Iran in 2019, researchers found sexual function in females (arousal, orgasm, lubrication, pain during intercourse, satisfaction) in the intervention group was significantly increased compared to females in the control group that had no date palm.
Infertility and infertility management affects different dimensions of a couple’s life. Sexual dysfunctions can appear in both partners and might provoke problems in every stage of sexual response. Infertility negatively affects the sexuality of infertile couples.
Numerous studies show that infertile women have lower sexual function than fertile women. Sexual satisfaction is strongly affected by the consequences of infertility such as reduced self-esteem, feelings of depression and anxiety, and failed sexual relationships.
The intervention group was given a palm date capsule and the control group was given a placebo. The starch powder was applied to prepare the placebo capsules.
Also, all areas of male sexual function (erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction) significantly increased in the intervention group compared to the control group.
Infertility is not only a medical problem but also affects all personal dimensions and social life of most infertile individuals. Infertile couples are more prone to psychological problems (anxiety, depression, and stress), which may result in marital distress, social dysfunction (stigma, social exclusion, and feelings of failure), and reduced quality of life.
Infertility and infertility management affects different dimensions of a couple’s life. Sexual dysfunctions can appear in both partners and might provoke problems in every stage of sexual response. Infertility negatively affects the sexuality of infertile couples.
Numerous studies show that infertile women have lower sexual function than fertile women. Sexual satisfaction is strongly affected by the consequences of infertility such as reduced self-esteem, feelings of depression and anxiety, and failed sexual relationships.
Dates palm is known to have come from what is now Iraq. In Nigeria, dry and soft date fruits are sold out for consumption. However, in the northern part, they are added to the locally brewed alcoholic beverage to help reduce the intoxicating power.
Dates are a good source of energy and vitamins and important elements such as phosphorus, iron, potassium and a significant amount of calcium. It is also rich in phenolic compounds possessing free radical scavenging and antioxidant activity.
Since ancient times, the date palm has been used in Greece, China and Egypt to treat infertility and increase sexual desire and fertility in females. There are few studies on the effect of date palms on male and female sexual function in human beings.
Besides, studies have shown that the various parts of its plant are widely used in traditional medicine for the treatment of various disorders which include memory disturbances, fever, inflammation, paralysis, loss of consciousness and nervous disorder.
Culled from Tribune online.

 

The researchers suggested that the improvement in male and female sexual function can be due to active ingredients and increased levels of sex hormones following the consumption of date palms since studies indicated that increasing sex hormones are effective in sexual function.

They, however, recommended more studies with a longer duration on the use of date palms on sex hormone levels in infertile couples.

Previously, a study revealed that using date palms in postmenopausal women for 1 month had a positive and significant impact on sexual desire and arousal.  Another suggested that using date palms had a positive impact on orgasm, satisfaction and lubrication in women and also reduced pain during intercourse in women.

In the laboratory, administering date palms to male rats and measuring their sexual behaviours, researchers showed that sexual behaviour parameters (number of ejaculations, number of intercourse) increased compared to the control group.

 

 

Continue Reading

Trending